6 GI Studies That Could Shift IBD Care and CRC Screening - Medscape

What To Know

Risankizumab: A randomized study of risankizumab (720 mg induction, 360 mg maintenance) in moderate-to-severe Crohn’s disease showed higher clinical response and improved CDAI and endoscopic remission through week 24 versus placebo; benefits were seen in both advanced-therapy–naive patients and those with prior biologic/JAK inhibitor failure.

Guselkumab: Post hoc analyses comparing subcutaneous guselkumab (100/200 mg) with ustekinumab and placebo suggested greater improvement in intestinal stenosis over extended follow-up (to week 96) and showed differences in fibroblast-related gene-expression modules, raising interest in effects on fibrostenotic disease.

Icotrokinra: An investigational oral peptide targeting the IL-23 pathway (doses 100–400 mg) maintained responses through week 76 in a long-term extension with high on-treatment retention and no new safety signals reported; this is an oral IL-23–targeted approach still under regulatory review.

Antidrug antibody/infliximab: The article also references a study on the predictive value of prior antidrug antibodies for infliximab response (details in the full article).